Neuroscience:
Our other therapy areas

    • {%buzitemName%}
        {%buzbrandMenuItems%}
    • {%bitemName%} {%barrowSpan%}
        {%bsubBrandMenuItems%}
    • {%sbitemName%} {%sbarrowSpan%}
        {%sbproductMenuItems%}
    • {%pitemKeyName%} {%pitemBadges%} {%parrowSpan%}
      {%pselfProduct%}
    • {%mNavitemName%}
      • {%lScountries%}
    • {%allMenuItem%}
      • {%cSlanguages%}

      • This website is intended for Healthcare Professionals working in Ireland

      aquipta-logo-white-registration-mark
      Prescribing Information
      CONTACT US
      RESOURCES AND EVENTS

       

       

      AQUIPTA® is indicated for prophylaxis of migraine in adults who have at least 4 migraine days per month.1

      AQUIPTA® was evaluated for the prophylaxis of migraine in multiple studies in chronic and episodic migraine.1

      To learn more, click on the buttons below

       
      Episodic_Migraine_Thumbnail
      Click here to learn more
      Chronic_Migraine_Thumbnail
      Click here to learn more

       

      References:

      1. AQUIPTA® Summary of Product Characteristics (Ireland).

       

      IE-AQP-250023 Date of Preparation: October 2025

      Our therapy areas
      Haematology
      Neurology
      Additional info
      Privacy Policy
      Terms and Conditions

       

      Reporting an Adverse Event: Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via Health Products Regulatory Authority (HPRA) Pharmacovigilance. www.hpra.ie.

       

      This website is intended for Healthcare Professionals working in Ireland
      Copyright© 2025 AbbVie Inc.

      Unless otherwise specified, all product names appearing in this internet site are trademarks owned or licensed by AbbVie Inc., its subsidiaries or affiliates. No use of any AbbVie trademark, trade names or trade dress in this site may be made without the prior written authorisation of AbbVie Inc., except to identify the product or services of the company

      AbbVie Pro is developed and funded by AbbVie Limited

      AbbVie Limited, a private company limited by Shares, and a member of the AbbVie group of companies.

      Registered in Ireland with Company Number 510846.

      Local contact details: 14 Riverwalk, Citywest Business Campus, Dublin 24, D24 XN32, Ireland.
      Tel (0) 1 4287900. www.abbvie.ie

      Date of Preparation: October 2025 | IE-ABBV-220078